Squarepoint
KYMR icon

Squarepoint’s Kymera Therapeutics KYMR Stock Holding History

Squarepoint’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
97,189
+84,350
+657% +$7.25M 0.01% 1043
2026
Q1 		$1.07M Sell
12,839
-146,587
-92% -$11.6M ﹤0.01% 2724
2025
Q4 		$12.4M Sell
159,426
-191,820
-55% -$13M 0.01% 982
2025
Q3 		$19.9M Buy
351,246
+317,922
+954% +$14.3M 0.02% 751
2025
Q2 		$1.45M Sell
33,324
-15,865
-32% -$546K ﹤0.01% 2335
2025
Q1 		$1.35M Buy
49,189
+815
+2% +$29.7K ﹤0.01% 2403
2024
Q4 		$1.95M Sell
48,374
-25,151
-34% -$1.14M ﹤0.01% 2447
2024
Q3 		$3.48M Sell
73,525
-35,038
-32% -$1.55M 0.01% 1676
2024
Q2 		$3.24M Buy
108,563
+23,312
+27% +$807K 0.01% 1685
2024
Q1 		$3.43M Buy
85,251
+57,053
+202% +$2.04M 0.01% 1725
2023
Q4 		$718K Sell
28,198
-2,190
-7% -$39.2K ﹤0.01% 2752
2023
Q3 		$422K Buy
+30,388
New +$611K ﹤0.01% 2922
2023
Q1 		– Sell
-21,878
Closed -$546K – 3518
2022
Q4 		$546K Sell
21,878
-97,003
-82% -$2.59M ﹤0.01% 2226
2022
Q3 		$2.59M Buy
118,881
+39,553
+50% +$1.04M 0.01% 1145
2022
Q2 		$1.56M Buy
+79,328
New +$1.85M 0.01% 1341
2021
Q4 		– Sell
-14,499
Closed -$852K – 3358
2021
Q3 		$852K Sell
14,499
-34,316
-70% -$1.99M ﹤0.01% 1655
2021
Q2 		$2.37M Buy
48,815
+34,404
+239% +$1.49M 0.01% 1088
2021
Q1 		$560K Buy
+14,411
New +$867K ﹤0.01% 1936
2020
Q4 		– Sell
-9,045
Closed -$292K – 3109
2020
Q3 		$292K Buy
+9,045
New +$276K ﹤0.01% 1815

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Squarepoint's KYMR Position: Q2 2026 in Review

Squarepoint increased its Kymera Therapeutics (KYMR) stake by 657% in Q2 2026, buying an estimated $7.25M and bringing the position to 97,189 shares worth $11.1M. The position accounts for 0.01% of the portfolio, ranked #1043.

Squarepoint first reported a position in KYMR in Q3 2020 and has held it in 19 quarters since. The position peaked at $19.9M in Q3 2025. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Squarepoint held 97,189 shares of Kymera Therapeutics worth $11.1M as of Q2 2026.
  • Squarepoint bought 84,350 Kymera Therapeutics shares in Q2 2026, an estimated $7.25M.
  • Kymera Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1043 holding.
  • Squarepoint first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 19 quarters since.
  • Squarepoint's Kymera Therapeutics position peaked at $19.9M in Q3 2025.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.